

CLAIMS

1. A fusion polypeptide in the form of a monomer comprising:
 - (i) the amino acid sequence of the endothelin A receptor ligand binding domains of SEQ ID NO: 1;
 - 5 (ii) the amino acid sequence of the endothelin A receptor ligand binding domains of SEQ ID NO: 2;
 - (iii) the amino acid sequence of the endothelin A receptor ligand binding domains of SEQ ID NO: 3; or
 - (iv) the amino acid sequence of the endothelin A receptor ligand binding domains of
10 SEQ ID NO: 4.
2. A fusion polypeptide according to Claim 1, fused to the Fc portion of human IgG1.
3. A fusion polypeptide according to Claim 2, which comprises the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4.
4. A recombinant nucleic acid molecule encoding a fusion polypeptide according to Claim
15 3.
5. A vector comprising a recombinant nucleic acid molecule according to Claim 4.
6. A vector according to Claim 5, in which the nucleic acid molecule encoding the fusion polypeptide is operatively linked to an expression control sequence.
7. A fusion polypeptide according to any of Claims 1 to 3 for use in a method of treating
20 an endothelin-1 related disease or disorder.
8. A fusion polypeptide for use according to Claim 7, in which the endothelin-1 related disease or disorder is preeclampsia, a cardiovascular disease or a neurodegenerative disease.
9. A fusion polypeptide capable of binding endothelin-1 to form a non-functional complex, in which the polypeptide molecule comprises one or more of the ETA receptor ligand-binding
25 domains of Claim 1.